drugset / Trial / NCT01618877

A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers

NCT01618877

Phase 1 Completed 24 enrolled UCB Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The part B of N01362 is to assess the pharmacokinetic profile of Levetiracetam 1500 mg intravenous (iv) infusion during repeated dosing in Chinese healthy volunteers.

Timeline

Start
2012-05
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 1.5 mg Intravenous

Indications

No indication recorded.